Literature DB >> 11940363

Stent supported coronary angioplasty in patients with severe ventricular dysfunction.

Chengxiang Li1, Guoliang Jia, Wenyi Guo, Weijie Li.   

Abstract

OBJECTIVE: To assess the immediate- and long-term outcomes of stent supported coronary angioplasty in patients with severe left ventricular dysfunction.
METHODS: Seventy-four consecutive patients with angiographic left ventricular ejection fractions < or = 40% underwent percutaneous coronary angioplasty, including 61 (81%) with stent back-up. Clinical follow-up (29.1 +/- 22.9 months) data were obtained in all clinically successful patients.
RESULTS: Angiographic success was achieved in 120 (89.5%) of 134 lesions. Clinical success was obtained in 66 (89.2%) patients with 1.4% procedure related mortality, 2.7% myocardial infarction and zero need of emergent bypass surgery. NYHA class reduction > or = 1 was seen in 29 (73%) of 40 successfully treated congestive heart failure patients at 6 months after the procedure. During long-term follow-up, 58 (87.9%) of 66 patients with clinical success were alive, including 44 (68.6%) free from cardiac events.
CONCLUSIONS: Patients with severe left ventricular dysfunction treated with stent supported PTCA experience a high rate of success, low procedure related mortality and satisfactory long-term survival.

Entities:  

Mesh:

Year:  2002        PMID: 11940363

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  2 in total

Review 1.  Revascularization for patients with severe coronary artery disease and left ventricular dysfunction.

Authors:  Tapas Ghose; Randall C Thompson
Journal:  Curr Cardiol Rep       Date:  2006-07       Impact factor: 2.931

2.  Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction.

Authors:  M Alidoosti; M Salarifar; A M Zeinali; S E Kassaian; M R Dehkordi; M S Fatollahi
Journal:  Cardiovasc J Afr       Date:  2008 Jan-Feb       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.